|
|
|
|
|
|
|
|
|
12.03.26 - 21:33
|
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire EN)
|
|
|
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market....
|
|
|
08.01.26 - 22:33
|
Cellectis Announces 2026 Strategy and Catalysts (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026....
|
|
|
|
|
15.12.25 - 23:42
|
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel (cema-cel). This decisive win reconfirmed Allogene's full development and commercial control of cema-cel in the United States, all EU Member States, and the United Kingdom, while clearing the path to obtain full global commercialization rights from Servier....
|
|
|
15.12.25 - 22:54
|
Cellectis Announces Arbitral Decision in Dispute with Servier (GlobeNewswire EN)
|
|
|
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization Agreement entered into between Servier and Cellectis on March 6, 2019, as amended (the “License Agreement”)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.11.25 - 15:18
|
Cellectis to Present a Development Update for eti-cel at ASH 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the acceptance of two abstracts for poster presentation at the American Society of Hematology (ASH) 2025 annual meeting taking place from December 6 to 9, 2025, in Orlando, FL....
|
|
|
31.10.25 - 21:33
|
Cellectis to Report Third Quarter Financial Results on November 7, 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market....
|
|
|
|
|
16.10.25 - 13:03
|
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers (GlobeNewswire EN)
|
|
|
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company's leadership team and key opinion leaders will present the full Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel in r/r B-ALL....
|
|
|
|
|
07.10.25 - 08:42
|
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress (GlobeNewswire EN)
|
|
|
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting the strong potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy, along with a comprehensive study of TALE base editors (TALEB) off-targets in the nuclear genome, will be presented at the European Society of Cell and Gene Therapy (ESGCT) annual congress, that will take place on October 7-10, 2025, in Sevilla, Spain....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
